ShenZhen Lijian Pharmaceutical Co., Ltd.

This product has a wide range of antibacterial effects on both Gram-positive and Gram-negative bacteria, especially on Streptococcus and Pneumococcus among Gram-positive bacteria, and Gonorrhea, Borrelia, Escherichia coli, Serratia, Klebsiella, Proteus, and Haemophilus influenzae among Gram-negative bacteria. It has stronger antibacterial ability than other oral cephalosporins, and its mode of action is bactericidal. Since this product is extremely stable to β-lactamase produced by various bacteria, it also has excellent antibacterial power against bacteria that produce β-lactamase. The mechanism of action of this product is mainly to prevent the synthesis of bacterial cell walls.

This product is an oral broad-spectrum second-generation cephalosporin. Its antibacterial mechanism is to inhibit the synthesis of bacterial cell walls by binding to bacterial proteins. Cefuroxime has a wide range of antibacterial activity against pathogens and is stable against many β-lactamases, especially plasmid-mediated enzymes commonly found in Enterobacteriaceae.

This product is an oral broad-spectrum second-generation cephalosporin. Cefuroxime axetil is an esterified derivative of cefuroxime. After oral administration, it is hydrolyzed and deesterified after intestinal absorption to form active cefuroxime and exert antibacterial effects. Its mechanism of action is to inhibit the synthesis of bacterial cell walls by binding to bacterial proteins. Cefuroxime has a wide range of antibacterial activity against pathogens and is stable to many β-lactamases, especially plasmid-mediated enzymes commonly found in Enterobacteriaceae.

Cefixime is a third-generation oral cephalosporin that kills bacteria by inhibiting bacterial cell wall synthesis. It is stable to most beta-lactamases, and many strains producing penicillinase and cephalosporinase are still sensitive to this product. Cefixime has good antibacterial effects in vitro and in vivo against Gram-positive cocci such as pneumococci, Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). Cefixime also has antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but its clinical effectiveness has not yet been established. This product has poor antibacterial effect on Staphylococcus, and has no antibacterial effect on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, Clostridium, etc.

Cefixime is a third-generation oral cephalosporin that kills bacteria by inhibiting bacterial cell wall synthesis. It is stable to most beta-lactamases, and many strains that produce penicillinase and cephalosporinase are still sensitive to this product. Cefixime has good antibacterial effects in vitro and in vivo against Gram-positive cocci such as pneumococci, Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). Cefixime also has antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but its clinical effectiveness has not yet been established. This product has poor antibacterial effect on Staphylococcus, and has no antibacterial effect on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, Clostridium, etc.